Important Safety Information
Prescribing Information
Patient Support
Visit Our Patient Site

IMPORTANT SAFETY INFORMATION:

expand

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Do not use Sucraid® with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.

Indication

Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

Prescribing Information Patient Websites

Visit Patient Site

About CSID
+

What is Congenital Sucrase-Isomaltase Deficiency?

Congenital Sucrase-Isomaltase Deficiency (CSID) is a rare genetic disorder first discovered in 1960 by Weijers and colleagues.1 The disorder is caused by pathogenic mutations in the sucrase-isomaltase gene (SI).

It is a disease of the small intestine characterized primarily by a failure to metabolize sucrose for intestinal absorption.

Read More

  1. Weijers HA, van de Kamer JH, Mossel DA, Dicke WK. Diarrhoea caused by deficiency of sugar-splitting enzymes. Lancet. 1960;2(7145):296-297.
Order a 13C-Sucrose Breath Test
+

Order a 13C-Sucrose Breath Test

Do you have patients suffering with unresolved IBS-like symptoms including gas, bloating, diarrhea, and/or nausea? Could it be CSID? Order Breath Test kits* for your office.

Download Order Form

*Breath tests are provided at no charge and are not billed to the patient or any third party payor. Please do not charge for the administration or interpretation of this test.

Order Sucraid®
+

Order Sucraid®

Sucraid® is available by prescription only through a specialty pharmacy. Call 1-833-800-0122.

Here are the steps for filling a prescription for Sucraid® from the specialty pharmacy:

  • The physician must complete the Sucraid® Prescription Form and fax it to 1-866-850-9155
  • The specialty pharmacy will contact the patient directly to schedule delivery of Sucraid®
  • Sucraid® will be shipped to the patient’s home or the physician’s office
  • For refill orders or any questions, call the specialty pharmacy 1-833-800-0122

Download Prescription Form

Prescribing Information
+

What is Sucraid®?

Sucraid® is the only FDA-approved enzyme replacement therapy indicated for the treatment of genetically determined sucrase deficiency, which is a part of Congenital Sucrase-Isomaltase Deficiency (CSID).

Sucraid® is an enzyme replacement therapy that facilitates the breakdown of sucrose (sugar) into monosaccharides for absorption by the small intestine. It has been shown to help alleviate the gastrointestinal (GI) symptoms associated with CSID, and, as a result, patients can maintain a more normal diet that includes sucrose-containing foods.

Read More

Prior Authorization Forms
+

Prior Authorization Forms

Sucraid® is an orphan therapy that is distributed through a specialty pharmacy and requires supportive information. For information on diagnosis codes, testing information, and how to access our prior authorization database, click here.

Read More

Explore the eDetail
+

Explore the eDetail

Find more information about how Sucraid® treats CSID and to access breath test kits, dietary guides, testimonial videos, and more.

Learn More

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Do not use Sucraid® with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.

Indication

Sucraid®(sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).